| REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI and Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. Haematologica. Itálie: Ferrata Storti Foundation, 2019, vol. 104, No 5, p. "E222-E223", 2 pp. ISSN 0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.213157. |
Other formats:
BibTeX
LaTeX
RIS
@article{1524093,
author = {Reda, Gianluigi and Cassin, Ramona and Dovrtělová, Gabriela and Matteo, Cristina and Giannotta, Juri and D'Incalci, Maurizio and Cortelezzi, Agostino and Zucchetti, Massimo},
article_location = {Itálie},
article_number = {5},
doi = {http://dx.doi.org/10.3324/haematol.2018.213157},
keywords = {CNS involvement; Chronic Lymphocytic Leukemia; venetoclax},
language = {eng},
issn = {0390-6078},
journal = {Haematologica},
title = {Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement},
url = {http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract},
volume = {104},
year = {2019}
}
TY - JOUR
ID - 1524093
AU - Reda, Gianluigi - Cassin, Ramona - Dovrtělová, Gabriela - Matteo, Cristina - Giannotta, Juri - D'Incalci, Maurizio - Cortelezzi, Agostino - Zucchetti, Massimo
PY - 2019
TI - Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement
JF - Haematologica
VL - 104
IS - 5
SP - "E222-E223"
EP - "E222-E223"
PB - Ferrata Storti Foundation
SN - 03906078
KW - CNS involvement
KW - Chronic Lymphocytic Leukemia
KW - venetoclax
UR - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
L2 - http://www.haematologica.org/content/early/2019/02/07/haematol.2018.213157.abstract
N2 - Venetoclax, a selective inhibitor of BCL2, has shown promising efficacy in chronic lymphocytic leukemia (CLL) both as single agent or in combination therapy. Central nervous system involvement (CNSi) is a rare complication of CLL and is reported in approximately 0.4% of patients. Therapeutic guidelines have not yet been established and prognosis for these patients is poor. Few cases of CLL with CNSi have been reported until now, and ibrutinib was successfully used due to its ability to penetrate the blood-brain barrier.
ER -
REDA, Gianluigi, Ramona CASSIN, Gabriela DOVRTĚLOVÁ, Cristina MATTEO, Juri GIANNOTTA, Maurizio D'INCALCI, Agostino CORTELEZZI and Massimo ZUCCHETTI. Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. \textit{Haematologica}. Itálie: Ferrata Storti Foundation, 2019, vol.~104, No~5, p.~''E222-E223'', 2 pp. ISSN~0390-6078. Available from: https://dx.doi.org/10.3324/haematol.2018.213157.
|
